<p dir="ltr">In the three conducted studies, we investigated the role of serum albumin in metabolic processes, particularly in lipid metabolism and glucoregulation. The first study explored how disrupting the binding of free fatty acids (FFA) to circulating albumin affects lipid metabolism and glucose control. Male and female albumin knockout mice exhibited significantly reduced plasma FFA levels, hepatic lipid content, and blood glucose during tolerance tests compared to wild-type mice. Additionally, albumin deficiency led to changes in adipose tissue gene expression, indicating the importance of albumin and plasma FFA concentration in metabolic regulation. In the second study, the focus was on determining if impeding serum albumin's function in transporting FFAs could prevent hepatic steatosis and metabolic dysfunction in obesity. Albumin knockout mice, despite being obese due to a high-fat diet, showed lower plasma FFA levels, improved glucose tolerance, and reduced hepatic lipid accumulation compared to wild-type mice. Elevated gene expression in liver and adipose tissues suggested albumin's involvement in hepatic lipid accumulation and glucose metabolism in obesity. Lastly, in the third study, we examined the phenotype of heterozygous albumin knockout mice and compared it to wild-type and homozygous knockout mice. While homozygous knockout mice exhibited improved glucoregulation and reduced plasma FFA concentration, heterozygous knockout mice did not show significant improvements compared to wild-type mice. The findings imply that a minor suppression of albumin expression may not be adequate to enhance glucoregulation. In summary, the studies emphasize the crucial role of serum albumin in metabolic processes, illustrating how disrupting FFA binding to albumin leads to improved glucose control and reduced hepatic lipid accumulation. However, minor suppression of albumin expression may not effectively enhance metabolic health. These findings provide valuable insights into potential therapeutic interventions targeting the albumin-FFA pathway to improve metabolic outcomes.</p><p dir="ltr"><br></p>

The unfolded protein response (UPR) is composed of three highly conserved pathways (ATF6, IRE1, PERK). Cellular stressors induce protein misfolding and aggregation in the endoplasmic reticulum (ER). This signaling pathway maintains protein homeostasis when there is stress in the ER. When the UPR is activated, the eukaryotic initiation factor 2 alpha (eIF2α) becomes phosphorylated, which inhibits global mRNA translation. If ER stress remains chronically unmitigated, the UPR induces apoptosis. GADD34 and CReP shift in expression when the UPR is activated and work as phosphatases and dephosphorylate eIF2α in a feedback loop, allowing protein synthesis to resume. Several human diseases, including fatty liver disease (FLD) are affected by cell stress from improper protein folding and accumulation, making the UPR a therapeutic target. Previous studies have indicated the UPR to both cause or become activated by FLD, depending on the duration of cellular stress. At least 25% of humans worldwide have steatosis, and zebrafish are a powerful model organism for FLD studies. Their embryos are easily obtained, and the liver develops quickly in their transparent larvae, which allows us to visualize the development of fat in the liver. It is unknown how exactly the UPR is involved in inducing lipogenesis in hepatocytes. We sought to better understand the link between UPR activation and steatosis. Pharmacological treatments with various drugs, some of which induce ER stress, were administered over different durations in zebrafish embryos and subsequently the expression of UPR network and lipogenesis genes were quantified through RT-qPCR. To visualize whether these drugs induced steatosis, zebrafish livers were stained with Oil Red O and imaged. Our results indicate that all chronic durations of pharmacological treatments resulted in fatty liver, and the expression of atf6 decreased in response to treatment that prevents the dephosphorylation of eIF2α. This data provides insight pertaining to the activity of the UPR network during FLD in zebrafish models.

INTRODUÇÃO E OBJETIVOS: A doença hepática gordurosa não alcoólica (DHGNA) tem sido associada ao carcinoma hepatocelular (CHC), muitas vezes em paciente com hepatopatia avançada. Este estudo objetivou avaliar o efeito do sorafenibe no modelo experimental de CHC avançado secundário à DHGNA, padronizar o PET com 18F-FDG para avaliar o CHC neste modelo e avaliar se há relação entre o grau de avidez pelo 18F-FDG e o grau de diferenciação tumoral do CHC. METODOLOGIA: Estudo foi aprovado pela Comissão de Ética no Uso de Animais. Foram utilizados trinta ratos Sprague-Dawley, machos, com 3 meses de vida, pesando entre 300-400g. O CHC secundário à DHGNA foi induzido pela combinação de dieta hiperlipídica deficiente em colina e dietilnitrosamina na dose de 100 mg/ L na água de beber ad libitum por 16 semanas. Após este período foram suspensos os estímulos carcinogênicos, realizou-se ultrassonografia abdominal para caracterização dos nódulos hepáticos maiores que 2 mm, e foi feita a divisão dos dois grupos segundo randomização e iniciada a administração diária do fármaco por gavagem durante 3 semanas: Controle (n=10) - 1 mL salina, Sorafenibe (n=20): 5mg/ kg/ dia. Ao término do tratamento, os animais realizaram PET (Gamma Medica-Ideas, USA) com 18F-FDG (média de 18F-FDG injetada de 1,02 ± 0,17 mCi ou 37,7 ± 6,29 MBq). Três dias após o PET, os animais foram anestesiados e foi feita a eutanásia, quando foi coletado material hepático. As lâminas foram avaliadas, por patologista veterinário experiente, na coloração de hematoxilina-eosina e imunohistoquímica para glutamina sintetase, antígeno específico de hepatócitos 1 e citoqueratina-19. RESULTADOS: A mortalidade nos dois grupos foi de 60% (p=0,07). Os achados ultrassonográficos mostraram grupos homogêneos com média de nódulos por animal: 4,88 ± 2,75 no controle e 4,95 ± 3,11 no sorafenibe (p=0,48). Na 19ª semana, viu-se que a média de lesões hipercaptantes por animal no PET foi de 4,37 ± 1,59 no grupo sorafenibe e 8,5 ± 3,7 no controle (p=0,006). A avidez máxima do 18F-FDG (SUVmáx) foi diferente entre os grupos estudados: 2,4 ± 1,98 no sorafenibe e 3,8 ± 1,74 no controle (p=0,01). Houve correlação direta entre o CHC pouco diferenciado/indiferenciado e os maiores valores de SUVmed (R2 = 0,34, p=0,04), SUVmax (R2 = 0,44, p=0,01), relação Tumor SUVmax/Fígado SUVmax (R2 = 0,42, p=0,02) e relação Tumor SUVmax/ Músculo SUVmax (R2 = 0,54, p=0,006). A média por animal de CHC confirmado pela histologia foi menor no grupo sorafenibe que no controle (5,5 ± 1,5 vs 3,3 ± 0,48, p=0,01). E o grupo tratado com sorafenibe apresentou mais CHC bem diferenciado que o controle (39% vs 5%, respectivamente, p=0,01), bem como, menor presença de CHC pouco diferenciado que o grupo controle (52% vs 81%, p-0,003). CONCLUSÃO: O sorafenibe reduziu o número médio de CHC, a agressividade dos CHC e menor SUVmax dos tumores. A metodologia do PET foi padronizada para este modelo animal específico. O PET 18F-FDG pode ser utilizado para avaliar não invasivamente o grau de diferenciação histológica do CHC, pois valores maiores de SUVmed, SUVmax, Tumor SUVmax/Fígado SUVmax e Tumor SUVmax/ Músculo SUVmax foram correlacionados com CHC pouco diferenciado / BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) has been linked to hepatocellular carcinoma (HCC), often in patients with advanced liver disease. This study aimed to: assess the effect of sorafenib in the experimental model of NAFLD related HCC, standardize PET 18F-FDG to be an assessment tool of HCC in this model and to assess if there is a correlation between the degree of avidity for 18F-FDG and the degree of tumor differentiation. METHODS: The ethics committee on animal use approved this study. Thirty male sprague-dawley rats were used, weighing between 300-400g. NAFLD related HCC was induced by the combination of fat and choline deficient diet with diethylnitrosamine (100 mg/L) in drinking water for 16 weeks. After this period these carcinogenic stimuli were suspended, and liver nodules were identified by abdominal ultrasound. Two groups were randomized: control (n=10) and treatment (n=20). Rats received daily gavage administration of 1 mL saline in the control group and sorafenib (5mg/kg/day) in the treatment group. After treatment, animals performed PET (Gamma Medica-Ideas, USA) with 18F-FDG (average of 18F-FDG injected 1.02 ± 0.17 mCi or 37.7 ± 6.29 MBq). Three days after the PET, the animals were anesthetized and euthanized. Histological aspect was evaluated by experienced veterinary pathologist. RESULTS: The mortality in both groups was 60% (p = 0.07). The sonographic findings showed homogeneous groups with average nodules per animal of: 4.88 ± 2.75 in control and 4.95 ± 3.11 in sorafenib (p = 0.48). On the 19th week, it was observed that the average hypercaptant lesion per animal in PET was 4.37 ± 1.59 in the sorafenib group and 8.5 ± 3.7 in control group (p = 0.006). Average SUVmax was different between groups: 2.4 ± 1.98 in the sorafenib group and 3.8 ± 1.74 in the control group (p = 0.01). A direct correlation was found between the poorly differentiated HCC and larger values of: SUVmed (R2 = 0.34, p = 0.04), SUVmax (R2 = 0.44, p = 0.01) tumorSUVmax / LiverSUVmax ratio (R2 = 0.42, p = 0.02) and tumorSUVmax / MuscleSUVmax ratio (R2 = 0.54, p = 0.006). HCC average per animal was lower in the sorafenib group than in the control group (5.5 ± 1.5 vs. 3.3 ± 0.48; p = 0.01). And sorafenib group had more well differentiated HCC (39% vs 5%, respectively, p = 0.01) and lower presence of poorly differentiated HCC (52% vs 81%, p -0.003) than the control group. CONCLUSION: Sorafenib reduced the average number of HCC, the aggressiveness of HCC and lowered values of tumors SUVmax. The methodology of PET was standardized for this particular animal model. PET 18F-FDG can be used noninvasively to assess the degree of histological differentiation of HCC, as higher values of SUVmed, SUVmax, tumorSUVmax/ LiverSUVmax ratio and tumorSUVmax / MuscleSUVmax ratio were correlated with poorly differentiated HCC

INTRODUÇÃO E OBJETIVOS: A doença hepática gordurosa não alcoólica (DHGNA) tem sido associada ao carcinoma hepatocelular (CHC), muitas vezes em paciente com hepatopatia avançada. Este estudo objetivou avaliar o efeito do sorafenibe no modelo experimental de CHC avançado secundário à DHGNA, padronizar o PET com 18F-FDG para avaliar o CHC neste modelo e avaliar se há relação entre o grau de avidez pelo 18F-FDG e o grau de diferenciação tumoral do CHC. METODOLOGIA: Estudo foi aprovado pela Comissão de Ética no Uso de Animais. Foram utilizados trinta ratos Sprague-Dawley, machos, com 3 meses de vida, pesando entre 300-400g. O CHC secundário à DHGNA foi induzido pela combinação de dieta hiperlipídica deficiente em colina e dietilnitrosamina na dose de 100 mg/ L na água de beber ad libitum por 16 semanas. Após este período foram suspensos os estímulos carcinogênicos, realizou-se ultrassonografia abdominal para caracterização dos nódulos hepáticos maiores que 2 mm, e foi feita a divisão dos dois grupos segundo randomização e iniciada a administração diária do fármaco por gavagem durante 3 semanas: Controle (n=10) - 1 mL salina, Sorafenibe (n=20): 5mg/ kg/ dia. Ao término do tratamento, os animais realizaram PET (Gamma Medica-Ideas, USA) com 18F-FDG (média de 18F-FDG injetada de 1,02 ± 0,17 mCi ou 37,7 ± 6,29 MBq). Três dias após o PET, os animais foram anestesiados e foi feita a eutanásia, quando foi coletado material hepático. As lâminas foram avaliadas, por patologista veterinário experiente, na coloração de hematoxilina-eosina e imunohistoquímica para glutamina sintetase, antígeno específico de hepatócitos 1 e citoqueratina-19. RESULTADOS: A mortalidade nos dois grupos foi de 60% (p=0,07). Os achados ultrassonográficos mostraram grupos homogêneos com média de nódulos por animal: 4,88 ± 2,75 no controle e 4,95 ± 3,11 no sorafenibe (p=0,48). Na 19ª semana, viu-se que a média de lesões hipercaptantes por animal no PET foi de 4,37 ± 1,59 no grupo sorafenibe e 8,5 ± 3,7 no controle (p=0,006). A avidez máxima do 18F-FDG (SUVmáx) foi diferente entre os grupos estudados: 2,4 ± 1,98 no sorafenibe e 3,8 ± 1,74 no controle (p=0,01). Houve correlação direta entre o CHC pouco diferenciado/indiferenciado e os maiores valores de SUVmed (R2 = 0,34, p=0,04), SUVmax (R2 = 0,44, p=0,01), relação Tumor SUVmax/Fígado SUVmax (R2 = 0,42, p=0,02) e relação Tumor SUVmax/ Músculo SUVmax (R2 = 0,54, p=0,006). A média por animal de CHC confirmado pela histologia foi menor no grupo sorafenibe que no controle (5,5 ± 1,5 vs 3,3 ± 0,48, p=0,01). E o grupo tratado com sorafenibe apresentou mais CHC bem diferenciado que o controle (39% vs 5%, respectivamente, p=0,01), bem como, menor presença de CHC pouco diferenciado que o grupo controle (52% vs 81%, p-0,003). CONCLUSÃO: O sorafenibe reduziu o número médio de CHC, a agressividade dos CHC e menor SUVmax dos tumores. A metodologia do PET foi padronizada para este modelo animal específico. O PET 18F-FDG pode ser utilizado para avaliar não invasivamente o grau de diferenciação histológica do CHC, pois valores maiores de SUVmed, SUVmax, Tumor SUVmax/Fígado SUVmax e Tumor SUVmax/ Músculo SUVmax foram correlacionados com CHC pouco diferenciado / BACKGROUND AND AIMS: Non-alcoholic fatty liver disease (NAFLD) has been linked to hepatocellular carcinoma (HCC), often in patients with advanced liver disease. This study aimed to: assess the effect of sorafenib in the experimental model of NAFLD related HCC, standardize PET 18F-FDG to be an assessment tool of HCC in this model and to assess if there is a correlation between the degree of avidity for 18F-FDG and the degree of tumor differentiation. METHODS: The ethics committee on animal use approved this study. Thirty male sprague-dawley rats were used, weighing between 300-400g. NAFLD related HCC was induced by the combination of fat and choline deficient diet with diethylnitrosamine (100 mg/L) in drinking water for 16 weeks. After this period these carcinogenic stimuli were suspended, and liver nodules were identified by abdominal ultrasound. Two groups were randomized: control (n=10) and treatment (n=20). Rats received daily gavage administration of 1 mL saline in the control group and sorafenib (5mg/kg/day) in the treatment group. After treatment, animals performed PET (Gamma Medica-Ideas, USA) with 18F-FDG (average of 18F-FDG injected 1.02 ± 0.17 mCi or 37.7 ± 6.29 MBq). Three days after the PET, the animals were anesthetized and euthanized. Histological aspect was evaluated by experienced veterinary pathologist. RESULTS: The mortality in both groups was 60% (p = 0.07). The sonographic findings showed homogeneous groups with average nodules per animal of: 4.88 ± 2.75 in control and 4.95 ± 3.11 in sorafenib (p = 0.48). On the 19th week, it was observed that the average hypercaptant lesion per animal in PET was 4.37 ± 1.59 in the sorafenib group and 8.5 ± 3.7 in control group (p = 0.006). Average SUVmax was different between groups: 2.4 ± 1.98 in the sorafenib group and 3.8 ± 1.74 in the control group (p = 0.01). A direct correlation was found between the poorly differentiated HCC and larger values of: SUVmed (R2 = 0.34, p = 0.04), SUVmax (R2 = 0.44, p = 0.01) tumorSUVmax / LiverSUVmax ratio (R2 = 0.42, p = 0.02) and tumorSUVmax / MuscleSUVmax ratio (R2 = 0.54, p = 0.006). HCC average per animal was lower in the sorafenib group than in the control group (5.5 ± 1.5 vs. 3.3 ± 0.48; p = 0.01). And sorafenib group had more well differentiated HCC (39% vs 5%, respectively, p = 0.01) and lower presence of poorly differentiated HCC (52% vs 81%, p -0.003) than the control group. CONCLUSION: Sorafenib reduced the average number of HCC, the aggressiveness of HCC and lowered values of tumors SUVmax. The methodology of PET was standardized for this particular animal model. PET 18F-FDG can be used noninvasively to assess the degree of histological differentiation of HCC, as higher values of SUVmed, SUVmax, tumorSUVmax/ LiverSUVmax ratio and tumorSUVmax / MuscleSUVmax ratio were correlated with poorly differentiated HCC

Chronic alcohol use results in accelerated liver injury, leading to alcoholic steatohepatitis, cirrhosis, and hepatocellular carcinoma. However, due to the complex nature of this disease process, a central, druggable mechanism has remained elusive. microRNAs are potent post-transcriptional regulators of gene expression. A single miRNA has the ability to regulate hundreds of pathways simultaneously, defining cellular fate and function. microRNA-122 (miR-122), the most abundant miRNA in hepatocytes, has a demonstrated role as an tumor suppressor, regulator of hepatocyte metabolism, and hepatic differentiation. In this dissertation I demonstrate the role of miR-122 on alcoholic liver disease (ALD) pathogenesis over four parts. In chapter II, I will demonstrate chronic alcoholic patients, free of neoplastic changes, have a reduction of miR-122 and that this miRNA regulates HIF-1α, a determinant of ALD pathogenesis. In chapter III, using hepatocytetropic adeno-associated virus 8 (AAV8) vector, I demonstrate that miR-122 inhibition mimics ALD pathogenesis, and furthermore, using hepatocyte-specific HIF-1α-null (HIF1hepKO) mice that this phenomenon is HIF-1α dependent. Given this finding, in chapter IV, I demonstrate that ectopic expression of miR-122 in vivo can reverse alcoholinduced liver damage, steatosis, and inflammation by directly targeting HIF-1α. Finally, in chapter V, I present evidence that alcohol-induced dysregulation of grainyhead-like proteins 1 and 2 (GRHL2), mediate the inhibition of miR-122 at the transcriptional level. These findings dissect a novel mechanistic regulatory axis of miR-122 and indicate a potential opportunity for restoration of miR-122 as a therapy in early ALD.

Indiana University-Purdue University Indianapolis (IUPUI) / My thesis comprises of two individual projects which revolve around the importance of post-transcriptional regulation in liver. My first project is studying the integrated miRNA – mRNA network in NAFLD. For fulfillment of the study we conducted a genome-wide study to identify microRNAs (miRs) as well as the miR-mRNA regulatory network associated with hepatic fat and NAFLD. Hepatic fat content (HFC), miR and mRNA expression were assessed in 73 human liver samples. Liver histology of 49 samples was further characterized into normal (n=33) and NAFLD (n=16). Liver miRNome and transcriptome were significantly associated with HFC and utilized to (a) build miR-mRNA association networks in NAFLD and normal livers separately based on the potential miR-mRNA targeting and (b) conduct pathway enrichment analyses. We identified 62 miRs significantly correlated with HFC (p < 0.05 with q < 0.15), with miR-518b and miR-19b being most positively and negatively correlated with HFC, respectively (p < 0.008 for both). Integrated network analysis showed that six miRs (miRs-30b*, 612, 17*, 129-5p, 204 and 20a) controlled ~ 70% of 151 HFC-associated mRNAs (p < 0.001 with q < 0.005). Pathway analyses of these HFC-associated mRNA revealed their key effect (p<0.05) in inflammation pathways and lipid metabolism. Further, significant (p<2.47e-4, Wilcoxon test) reduction in degree of negative associations for HFC-associated miRs with HFC-associated mRNAs was observed in NAFLD as compared to normal livers, strongly suggesting highly dysfunctional miR-mRNA post-transcriptional regulatory network in NAFLD. Our study makes several novel observations which provide clues to better understand the pathogenesis and potential treatment targets of NAFLD. My second project is based on uncovering important players of post-transcriptional regulation (RBPs) and how they are associated with age and gender during healthy liver development. For this study, we performed an association analysis focusing on the expression changes of 1344 RNA Binding proteins (RBPs) as a function of age and gender in human liver. We identify 88 and 45 RBPs to be significantly associated with age and gender respectively. Experimental verification of several of the predicted associations in the mouse model confirmed our findings. Our results suggest that a small fraction of the gender-associated RBPs (~40%) are likely to be up-regulated in males. Altogether, these observations show that several of these RBPs are important developmentally conserved regulators. Further analysis of the protein interaction network of RBPs associated with age and gender based on the centrality measures like degree, betweenness and closeness revealed that several of these RBPs might be prominent players in liver development and impart gender specific alterations in gene expression via the formation of protein complexes. Indeed, both age and gender-associated RBPs in liver were found to show significantly higher clustering coefficients and network centrality measures compared to non-associated RBPs. The compendium of RBPs and this study will help us gain insight into the role of post-transcriptional regulatory molecules in aging and gender specific expression of genes.

Master of Science / Department of Animal Sciences and Industry / Barry J. Bradford / The prevalence of fatty liver in transition dairy cattle has been reported to be as high as 50%. There are a few reliable on-farm diagnostic tools and even fewer methods to effectively prevent fatty liver. Non-alcoholic steatohepatitis, an advanced form of non-alcoholic fatty liver in humans, is accurately diagnosed with a commercial blood test that detects plasma cytokeratin-18 (CK18) fragments released during hepatocyte apoptosis. A study was performed using 89 Holstein cows in early lactation to determine if CK18 could serve as a novel indicator of liver triglyceride (TG) content. Although no previous work has been done with CK18 in bovine plasma, our results indicated that CK18 fragments were present in plasma. However, CK18 concentrations did not correlate with liver TG content or other measures of liver function, suggesting it is not a reliable diagnostic tool. Nevertheless, based on liver TG, plasma non-esterified fatty acid (NEFA), and plasma β-hydroxybutyric acid (BHBA) concentrations, this sample population as a whole was not suffering from severe metabolic problems or fatty liver, making it possible that plasma CK18 fragments are elevated only in the most extreme cases. Currently, there is no widely-adopted preventative strategy for fatty liver. A second study was performed to evaluate if encapsulated niacin (EN) could prevent liver TG accumulation during the transition period. Twenty-four primiparous (n=9) and multiparous (n=13) cows were randomly assigned to receive 0 or 24 g of dietary EN, beginning 3 weeks prior to expected calving until 21 days postpartum. Feeding EN did not influence liver TG content, but decreased plasma NEFA concentrations, suggesting inhibition of lipolysis. Multiparous EN cows also experienced depressed dry matter intake (DMI) in the 4 days prior to calving. However, even when EN reduced DMI, plasma NEFA was still suppressed. A novel finding was the prolonged clearance of caffeine in plasma on day 7 postpartum in EN-treated animals. In contrast to other studies, this dose and delivery method of EN did not result in an increase in plasma NEFA after EN treatment ended. These research projects determined that plasma CK18 is likely not a useful diagnostic tool for mild to moderate bovine fatty liver and that feeding EN can inhibit lipolysis but may influence DMI as well. This is one of the first studies into the metabolic effects of feeding EN, and further research is needed in this field.

To compare ultrasound-based acoustic structure quantification (ASQ) with established non-invasive techniques for grading and staging fatty liver disease.

A manipulação cirúrgica do fígado com esteato-hepatite pode levar a complicações pós-operatórias importantes. A N-acetilcisteína (NAC) apresenta efeito protetor em modelos de I/R hepática, bem como na doença hepática gordurosa não alcoólica. Porém, há carência de estudos relacionados a seu efeito em lesões de I/R em fígado com esteato-hepatite. Portanto, esse estudo teve como objetivo avaliar o efeito da NAC sobre a reação inflamatória, estresse oxidativo e morte celular induzidos pela I/R hepática associada à esteato-hepatite. Foram utilizados camundongos C57BL/6J, machos, com oito semanas e peso entre 25 e 30 gramas, que receberam ração normal AIN-93M ou deficiente em Metionina e Colina (DMC) de acordo com o grupo de estudo. A NAC (150mg/kg) foi administrada 15 minutos antes da isquemia (DMC-I/R+NAC). Nos grupos DMC-I/R e DMC-I/R+NAC, os animais foram submetidos a 30 minutos de isquemia e 24 horas de reperfusão. Após esse período, o sangue foi coletado, para análise bioquímica das transaminases, e o fígado, removido cirurgicamente para avaliação histopatológica, dosagem das citocinas IL-1beta, TGF-beta1 e IFN-y, nitrito e Substâncias Reativas ao Ácido Tiobarbitúrico (TBARS), análise da expressão celular de Bcl-2 e apoptose (TUNEL). A histopatologia mostrou redução de focos inflamatórios no grupo DMC-I/R+NAC. Os níveis AST foram elevados no grupo DMC-I/R enquanto que os de ALT diminuíram em relação ao controle. No grupo DMC-I/R+NAC houve redução em ambas as transaminases, sendo significante apenas para a avaliação de AST. A produção das citocinas IL-1beta e TGF-beta1 foi elevada no fígado esteatótico de camundongos submetidos à I/R em comparação aos animais com fígado normal; porém, o tratamento com NAC promoveu uma redução significante dessas citocinas. A análise do estresse oxidativo mostrou que os animais com esteato-hepatite submetido à I/R tiveram as concentrações de TBARS e de nitrito elevadas em relação aos camundongos com fígado normal. No entanto, ao receberem o tratamento com NAC, esses animais apresentaram uma redução de ambos. A análise da expressão de Bcl-2 mostrou que essa proteína estava elevada em camundongos com fígado normal, e reduzida na presença de esteato-hepatite ou quando esta afecção está associada à I/R. A NAC, nesse caso, promoveu o aumento da expressão de Bcl-2 em camundongos com esteato-hepatite submetido à I/R. Esse resultado estava associado aos dados de apoptose, nos quais foi observado aumento do número de células apoptóticas no fígado esteatótico de camundongos em que a I/R foi induzida e redução nos animais tratados com NAC. Desta forma, conclui-se que o uso da NAC promove efeitos benéficos sobre o fígado de camundongos com esteato-hepatite associada à lesão de I/R por meio da redução do infiltrado inflamatório, das concentrações de IL-1beta e TGF-beta1, do estresse oxidativo e da morte celular / The surgical manipulation of the liver with steatohepatitis may lead to important postoperative complications. The N-acetylcysteine (NAC) has a protective effect in hepatic I/R models, as well as in non-alcoholic fatty liver disease. However, there is a lack of studies related to its effect inI/R injury to liver with steatohepatitis. Therefore, the purpose of this study was to assess the effect of NAC over inflammatory, oxidative stress and cell death induced by hepatic I/R associated to steatohepatitis. The mice used were C57BL/6J, male, eight weeks old and weighing between 25 and 30 grams, which received normal diet AIN-93M or Methionine and Choline-deficient diet (DMC) according to their study group. The NAC (150mg/kg) was administered 15 minutes before the ischemia (DMC-I/R+NAC). In groups DMC-I/R and DMC-I/R+NAC, the animals were submitted to 30 minutes of ischemia and 24 hours of reperfusion. After this period, blood was collected, for biochemical analysisof transaminases, and the liver, surgically removed for histopathological assessment, dosage of cytokines levels IL-1beta, TGF-beta1 and IFN-y, nitrite and Reactive Substances to Thiobarbituric Acid (TBARS), analysis of cell expression of Bcl-2 and apoptosis (TUNEL). The histopathology showed a reduction of inflammatory foci in DMC-I/R+NAC group. The AST levels were elevated in DMC-I/R group while the ALT reduced in comparing to control. In the DMC-I/R+NAC group there was a reduction in both transaminases, being significant only for AST assessment. The production of cytokines IL-1beta and TGF-beta1 was elevated in the liver with steatosis of mice submitted to I/R when compared to the animals with normal liver; however, the treatment with NAC provided a significant reduction of these cytokines. The oxidative stress analysis showed that the animals with steatohepatitis submitted to I/R had the concentrations of TBARS and nitrite elevated when compared to the mice with normal liver. However, when they received treatment with NAC, these animals presented a reduction in both. The analysis of the Bcl-2 expression showed that this protein was high in mice with normal liver, and reduced in the presence of steatohepatitis or when this affection is associated to I/R. A NAC, in this case, lead to an increase of Bcl-2 expression in mice with steatohepatitis submitted to I/R. This result was associated to data of apoptosis, where increase in the number of apoptotic cells in liver with steatosis of mice in which theI/R was induced and reduction in animals treated with NAC was observed. Therefore, the conclusion is that the use of NAC promotes beneficial effects on the liver of mice with steatohepatitis associated to I/R injury through the reduction of inflammatory infiltrate, of concentrations of IL-1beta and TGF-beta1, of oxidative stress and cell death

There are multiple immune mechanisms identified for persistence of hepatitis B virus (HBV) infection. This thesis considers the vital role that inhibitory receptors play in contributing to impairment of the adaptive immune system in chronic hepatitis B (CHB), and the potential role they play in the innate immune system, focusing on the inhibitory receptor leucocyte-associated immunoglobulin-like receptor (LAIR)-1. The unique aspect of this work is that for the first time LAIR-1 expression has been investigated on natural killer (NK) cells in CHB. Our striking findings of increased LAIR-1 expression on peripheral NK cells in CHB and an inverse correlation between expression and effector function suggest this inhibitory receptor could have a potential role in exhaustion of NK cells in CHB. We therefore additionally explored the expression of LAIR-1 on circulating NK cells from patients with hepatocellular carcinoma (HCC) and non-alcoholic fatty liver disease (NAFLD). The particular relevance of LAIR-1 to liver disease is that one of its major ligands is collagen. We demonstrated a downregulation of LAIR-1 expression on intrahepatic NK cells, which we postulate might occur following repetitive engagement with abundant collagen within the liver. In line with this, intrahepatic NK cells with a liver-resident (CXCR6+) phenotype had even lower LAIR-1 expression than liver infiltrating (non-resident, CXCR6-) NK cells. Furthermore, preliminary experiments display attenuation of the cytotoxic degranulation capacity (CD107a) by circulating NK cells from CHB patients upon exposure to plate-bound collagen. We demonstrate differential expression of LAIR-1 on NK cells in viral hepatitis, HCC and NAFLD and between peripheral and intrahepatic NK cells. Preliminary experiments demonstrate a role in inhibiting NK cell function suggesting this as a novel therapeutic target to harness the capacity of NK cells to control chronic infection and cancer.